Have a feature idea you'd love to see implemented?
Let us know!
KRON Kronos Bio Inc
Price (delayed)
$0.8743
Market cap
$52.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.43
Enterprise value
$1.56M
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated
Highlights
The company's revenue has surged by 146% YoY and by 17% QoQ
Kronos Bio's gross profit has soared by 146% YoY and by 17% from the previous quarter
The equity has declined by 38% year-on-year and by 10% since the previous quarter
Key stats
What are the main financial stats of KRON
Market
Valuations
Earnings
Shares outstanding
60.34M
Market cap
$52.76M
Enterprise value
$1.56M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.47
Price to sales (P/S)
5.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.16
Revenue
$9.86M
EBIT
-$85.59M
EBITDA
-$81.03M
Free cash flow
-$77.66M
Per share
Balance sheet
Liquidity
EPS
-$1.43
Free cash flow per share
-$1.29
Book value per share
$1.84
Revenue per share
$0.16
TBVPS
$2.49
Total assets
$150.02M
Total liabilities
$38.9M
Debt
$25.8M
Equity
$111.13M
Working capital
$112.54M
Debt to equity
0.23
Current ratio
8.32
Quick ratio
8.25
Net debt/EBITDA
0.63
Margins
Efficiency
Dividend
EBITDA margin
-821.4%
Gross margin
100%
Net margin
-867.7%
Operating margin
-943.6%
Return on assets
-48.2%
Return on equity
-64.6%
Return on invested capital
-71.4%
Return on capital employed
-63.6%
Return on sales
-867.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KRON stock price
How has the Kronos Bio stock price performed over time
Intraday
1.66%
1 week
2.74%
1 month
-8.93%
1 year
-25.27%
YTD
-30.06%
QTD
-12.56%
Financial performance
How have Kronos Bio's revenue and profit performed over time
Revenue
$9.86M
Gross profit
$9.86M
Operating income
-$93.08M
Net income
-$85.59M
Gross margin
100%
Net margin
-867.7%
The company's revenue has surged by 146% YoY and by 17% QoQ
Kronos Bio's gross profit has soared by 146% YoY and by 17% from the previous quarter
The operating margin has soared by 71% year-on-year and by 29% since the previous quarter
The net margin has soared by 71% YoY and by 29% QoQ
Growth
What is Kronos Bio's growth rate over time
Valuation
What is Kronos Bio stock price valuation
P/E
N/A
P/B
0.47
P/S
5.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.16
Kronos Bio's EPS has increased by 31% YoY and by 18% QoQ
KRON's P/B is 66% below its 5-year quarterly average of 1.4 and 6% below its last 4 quarters average of 0.5
The equity has declined by 38% year-on-year and by 10% since the previous quarter
The company's revenue has surged by 146% YoY and by 17% QoQ
KRON's P/S is 42% below its last 4 quarters average of 9.2
Efficiency
How efficient is Kronos Bio business performance
Kronos Bio's return on sales has surged by 71% YoY and by 29% QoQ
The company's return on invested capital fell by 29% YoY
The ROE fell by 16% YoY but it rose by 6% QoQ
Kronos Bio's ROA has decreased by 10% YoY but it has increased by 6% from the previous quarter
Dividends
What is KRON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KRON.
Financial health
How did Kronos Bio financials performed over time
The total assets has declined by 37% year-on-year and by 9% since the previous quarter
The total liabilities is down by 34% year-on-year and by 5% since the previous quarter
The debt is 77% lower than the equity
The equity has declined by 38% year-on-year and by 10% since the previous quarter
Kronos Bio's debt to equity has increased by 35% YoY and by 4.5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.